Patricia Allen Purchases 15,700 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Patricia Allen acquired 15,700 shares of the stock in a transaction dated Thursday, February 12th. The stock was acquired at an average cost of $24.85 per share, with a total value of $390,145.00. Following the transaction, the director owned 15,700 shares of the company’s stock, valued at approximately $390,145. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Zenas BioPharma Stock Performance

NASDAQ ZBIO opened at $26.40 on Friday. The business’s 50-day moving average price is $27.56 and its 200 day moving average price is $25.65. The company has a current ratio of 5.66, a quick ratio of 5.66 and a debt-to-equity ratio of 0.37. Zenas BioPharma, Inc. has a twelve month low of $6.11 and a twelve month high of $44.60. The company has a market capitalization of $1.42 billion, a PE ratio of -3.73 and a beta of -1.50.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Analysts Set New Price Targets

A number of brokerages have weighed in on ZBIO. Citigroup lifted their price target on shares of Zenas BioPharma from $27.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, October 28th. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Evercore initiated coverage on Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 price objective on the stock. Finally, Morgan Stanley lowered Zenas BioPharma from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $37.00 to $19.00 in a research note on Monday, January 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zenas BioPharma has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Institutional Investors Weigh In On Zenas BioPharma

A number of large investors have recently modified their holdings of ZBIO. Quarry LP lifted its position in Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Zenas BioPharma during the third quarter worth $30,000. GF Fund Management CO. LTD. acquired a new position in shares of Zenas BioPharma during the fourth quarter worth $38,000. BNP Paribas Financial Markets boosted its stake in shares of Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares during the period. Finally, CWM LLC grew its holdings in Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.